Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 11:07 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 224 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Substance Withdrawal Clear all
Terminated Phase 2 Interventional Results available

Preventing Alcohol Withdrawal With Oral Baclofen

NCT01937364
View directory record Official record
Conditions
Alcoholism, Alcohol Withdrawal
Interventions
Baclofen, Placebo
Drug
Lead sponsor
Essentia Health
Other
Eligibility
21 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
2
States / cities
Duluth, Minnesota • Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated May 5, 2017 · Synced Oct 20, 2026, 11:07 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

UW Withdraw From Tobacco Study

NCT04969198
View directory record Official record
Conditions
Tobacco Dependence
Interventions
Combination nicotine replacement therapy (Nicotine patch + nicotine mini-lozenge)
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
21 Years and older
Enrollment
232 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 8, 2025 · Synced Oct 20, 2026, 11:07 PM EDT
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

Phase 1 Study of Oral MG001

NCT07204171
View directory record Official record
Conditions
Safety and Tolerability in Healthy Subjects
Interventions
mitragynine, Placebo
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Oct 20, 2026, 11:07 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Project 2, Study 2: Extended Exposure to Low Nicotine Content Cigarettes in Opioid Abusers

NCT02250664
View directory record Official record
Conditions
Tobacco Use Disorder
Interventions
Very low nicotine content cigarettes
Other
Lead sponsor
University of Vermont
Other
Eligibility
18 Years to 70 Years
Enrollment
775 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
2
States / cities
Baltimore, Maryland • Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Dec 1, 2022 · Synced Oct 20, 2026, 11:07 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Phase IIa Study of AV411, a Glial Activation Inhibitor, for Opioid Withdrawal

NCT00723177
View directory record Official record
Conditions
Opioid-Related Disorders
Interventions
AV411, Placebo (PCB)
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
21 Years to 45 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 5, 2016 · Synced Oct 20, 2026, 11:07 PM EDT
Withdrawn Phase 3 Interventional Accepts healthy volunteers

Comparison of Three Opioid Detoxification Treatment Regimens

NCT03678792
View directory record Official record
Conditions
Opioid-Related Disorders, Opioid Withdrawal
Interventions
Buprenorphine/naloxone, Morphine, Tramadol
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 5, 2019 · Synced Oct 20, 2026, 11:07 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Medications Development for the Treatment of Cannabis Related Disorders

NCT01204723
View directory record Official record
Conditions
Nicotine Withdrawal, Marijuana Dependence, Cannabis Dependence, Nicotine Dependence, Cannabis Abuse
Interventions
Placebo Aprepitant, Active Aprepitant
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 45 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
2
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 1, 2012 · Synced Oct 20, 2026, 11:07 PM EDT
Completed Phase 1 Interventional

Buspirone for Opioid Tapering

NCT03521960
View directory record Official record
Conditions
Opioid-Related Disorders, Dependency (Psychology), Pain, Chronic, Opiate Withdrawal Syndrome
Interventions
Buspirone oral capsule, Placebo oral capsule
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 23, 2020 · Synced Oct 20, 2026, 11:07 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Varenicline OTC Trial on Efficacy and Safety

NCT03557294
View directory record Official record
Conditions
Tobacco Dependence, Withdrawal Symptoms, Smoking Cessation
Interventions
1.0mg Varenicline b.i.d., 0.5mg Varenicline b.i.d., 0.0mg placebo Varenicline b.i.d.
Drug
Lead sponsor
Arizona State University
Other
Eligibility
21 Years and older
Enrollment
313 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
2
States / cities
Phoenix, Arizona • Burbank, California
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 20, 2026, 11:07 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Cigarette Harm Reduction With Electronic Cigarette Use

NCT03473483
View directory record Official record
Conditions
Nicotine Dependence, Tobacco Toxicity, Nicotine Dependence, Cigarettes, Cardiovascular Risk Factor, Nicotine Withdrawal
Interventions
SREC
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
21 Years to 70 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 9, 2022 · Synced Oct 20, 2026, 11:07 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Nabilone for Cannabis Dependence: A Pilot Study

NCT01347762
View directory record Official record
Conditions
Cannabis Dependence, Marijuana Dependence
Interventions
Nabilone, Placebo
Drug
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years to 45 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 1, 2018 · Synced Oct 20, 2026, 11:07 PM EDT
Enrolling by invitation Phase 2Phase 3 Interventional

Effects of Ketone Supplementation on Acute Alcohol Withdrawal

NCT06173973
View directory record Official record
Conditions
Alcohol Use Disorder, Alcohol Withdrawal, Alcohol Dependence, Ketosis
Interventions
Kenetik; Ketone Concentrate, Isocaloric dextrose placebo
Dietary Supplement
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Wernersville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Oct 20, 2026, 11:07 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Oral Cannabidiol for Opioid Withdrawal

NCT04238754
View directory record Official record
Conditions
Opioid Withdrawal, Opioid Craving, Opioid Use Disorder
Interventions
Epidiolex, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 75 Years
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 29, 2023 · Synced Oct 20, 2026, 11:07 PM EDT
Completed Phase 2 Interventional

Comparing Gabapentin and Lorazepam for Treating Alcohol Withdrawal

NCT00011297
View directory record Official record
Conditions
Alcoholism
Interventions
gabapentin (Neurontin), lorazepam (Ativan)
Drug
Lead sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NIH
Eligibility
18 Years to 70 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2005
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 23, 2006 · Synced Oct 20, 2026, 11:07 PM EDT
Completed Not applicable Interventional

Transcutaneous Auricular Neurostimulation (tAN) for Symptoms of Opioid Withdrawal

NCT04075214
View directory record Official record
Conditions
Opioid-use Disorder, Opioid Withdrawal
Interventions
transcutaneous auricular neurostimulation (tAN)
Device
Lead sponsor
Spark Biomedical, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 19, 2021 · Synced Oct 20, 2026, 11:07 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Oxytocin Treatment of Alcohol Withdrawal

NCT01212185
View directory record Official record
Conditions
Alcohol Withdrawal
Interventions
intranasal oxytocin spray, intranasal spray without oxytocin
Drug · Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated May 13, 2014 · Synced Oct 20, 2026, 11:07 PM EDT
Withdrawn No phase listed Observational

Validation of a Pediatric-Specific Abstinence Syndrome Assessment Tool

NCT00792415
View directory record Official record
Conditions
Substance Withdrawal Syndrome
Interventions
Not listed
Lead sponsor
Banner Health
Other
Eligibility
2 Weeks to 18 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Mesa, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 11, 2025 · Synced Oct 20, 2026, 11:07 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

INIA Stress and Chronic Alcohol Interactions: Glucocorticoid Antagonists in Heavy Drinkers

NCT02989662
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Mifepristone, Placebo - Cap
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 55 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 30, 2025 · Synced Oct 20, 2026, 11:07 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Ambulatory Alcohol Detoxification With Remote Monitoring

NCT03582150
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Remote Monitoring with Ambulatory Detox
Device
Lead sponsor
Stanford University
Other
Eligibility
21 Years to 75 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Dec 16, 2022 · Synced Oct 20, 2026, 11:07 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Acute Pharmacokinetic and Pharmacodynamic Effects of "Tobacco-Free" Oral Nicotine Pouches in Smokers

NCT05335915
View directory record Official record
Conditions
Nicotine Withdrawal, Nicotine Addiction, Drug Effect
Interventions
Nicotine, Cigarette
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years and older
Enrollment
71 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Oct 20, 2026, 11:07 PM EDT
Terminated Phase 3 Interventional

A Bioavailability and Safety Study of Probuphine Versus Sublingual Buprenorphine in Patients With Opioid Dependence

NCT00768482
View directory record Official record
Conditions
Opioid Dependence
Interventions
Probuphine (buprenorphine implant), Sublingual Buprenorphine
Drug
Lead sponsor
Titan Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Fort Lauderdale, Florida
Source: ClinicalTrials.gov public record
Updated Dec 31, 2018 · Synced Oct 20, 2026, 11:07 PM EDT
Completed No phase listed Observational

Maternal Opioid Treatment: Human Experimental Research - Data Yield Appropriate Decisions

NCT04049799
View directory record Official record
Conditions
Opioid-use Disorder, Opioid Withdrawal, Neonatal Abstinence Syndrome, Neonatal Opioid Withdrawal Syndrome
Interventions
Medically-supervised withdrawal, Opioid agonist treatment, Comprehensive clinical care
Other · Behavioral
Lead sponsor
University of Vermont
Other
Eligibility
18 Years to 41 Years · Female only
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
4
States / cities
Asheville, North Carolina • Chapel Hill, North Carolina • Burlington, Vermont + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2024 · Synced Oct 20, 2026, 11:07 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy of Probuphine in the Treatment of Opioid Dependence

NCT00447564
View directory record Official record
Conditions
Opioid Dependence
Interventions
Probuphine, placebo
Drug
Lead sponsor
Titan Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
18
States / cities
Los Angeles, California • National City, California • Oceanside, California + 14 more
Source: ClinicalTrials.gov public record
Updated Dec 31, 2018 · Synced Oct 20, 2026, 11:07 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effects of Transcranial Direct Current Stimulation on Tobacco Withdrawal Symptoms

NCT01567982
View directory record Official record
Conditions
Nicotine Withdrawal, Tobacco Abstinence
Interventions
tDCS, prefrontal cortex and parietal cortex
Device
Lead sponsor
Yale University
Other
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 15, 2015 · Synced Oct 20, 2026, 11:07 PM EDT